SCHEMBL15534871

SCHEMBL15534871

COC(=O)[C@H]1CC[C@H](CNC(=O)c2c(N)cccc2F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CHRM1 P11229 4/20 0.43
CHRM3 P20309 1/20 0.43
CRBN Q96SW2 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
GNRHR P30968 1/20 0.40
PREP P48147 1/20 0.39
HDAC1 Q13547 2/20 0.39
AR P10275 3/20 0.38
HDAC6 Q9UBN7 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15534872 1.00 CCNA2 (0.45) CCNA2CDK2CHRM1CHRM3CRBN
SCHEMBL15535202 0.81 GNRHR (0.48) CNR1CNR2GNRHR
SCHEMBL15535203 0.81 GNRHR (0.48) CNR1CNR2GNRHR
SCHEMBL1666506 0.81 ALDH1A1 (0.48) CHRM1CNR1CNR2GNRHRHDAC1
SCHEMBL12798265 0.81 ALDH1A1 (0.48) CHRM1CNR1CNR2GNRHRHDAC1
SCHEMBL1668907 0.81 ALDH1A1 (0.48) CHRM1CNR1CNR2GNRHRHDAC1
SCHEMBL11893819 0.81 ALDH1A1 (0.48) CHRM1CNR1CNR2GNRHRHDAC1
SCHEMBL15534659 0.79 GNRHR (0.44) CNR1CNR2GNRHRHDAC1HDAC6
SCHEMBL15534658 0.79 GNRHR (0.44) CNR1CNR2GNRHRHDAC1HDAC6
Acetic Acid SCHEMBL11893957 0.78 ALDH1A1 (0.46) CHRM1GNRHRHDAC1HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013177349-A2 QUINAZOLINEDIONES AS TANKYRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-11-28 WO disclosed